Avantax Planning Partners, Inc. Fibrogen Inc Transaction History

Avantax Planning Partners, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $2,961 - $4,692	-78 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$56.3 - $67.25 $4,391 - $5,245	78 New	78 $5,000
Q2 2018 Aug 13, 2018	SELL	$44.9 - $64.95 $3,008 - $4,351	-67 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $3,038 - $4,130	67 New	67 $3,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Planning Partners, Inc. with notifications on news.